Bispecific Antibodies Achieve High Response Rates, Tolerable Adverse Effects in Multiple Myeloma

Source: Pharmacy Times articles

Bispecific antibodies have offered a new treatment approach in relapsed/refractory multiple myeloma, with promising results in preclinical studies for multiple cancers and hematological malignancies.
Read More